| 英文名 | (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate |
|---|---|
| 英文别名 |
1-Piperazinecarboxylic acid, 4-methyl-, (2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-2-[(1E,3E,5R)-1-methyl-5-(2-pyridinyl)-1,3-hexadien-1-yl]-12-oxooxacyclododec-4-en-6-yl ester
(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate |
| 描述 | H3B-8800是一种口服剪接调节剂,靶向含有WTor突变体SF3b(结合IC50为0.3-2 nM)的剪接体SF3b复合物；在体外生化测定中证明了突变体SF3B1诱导的经典剪接和异常剪接的剂量依赖性抑制。剪接体突变体诱导致死性癌细胞。血癌1期临床 |
|---|---|
| 参考文献 | References 1. Seiler M, et al. Nat Med. 2018 Feb 19. doi: 10.1038/nm.4493. 2. Finci LI, et al. Genes Dev. 2018 Feb 1;32(3-4):309-320. 3. Cancer Discov. 2018 Mar 2. doi: 10.1158/2159-8290.CD-RW2018-038. View Related Products by Target Spliceosome Blood Cancer |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 710.6±60.0 °C at 760 mmHg |
| 分子式 | C31H45N3O6 |
| 分子量 | 555.706 |
| 闪点 | 383.6±32.9 °C |
| 精确质量 | 555.330811 |
| LogP | 2.22 |
| 蒸汽压 | 0.0±2.4 mmHg at 25°C |
| 折射率 | 1.581 |
